Release Details

In accordance with Disclosure and Transparency Rule 5.6, LivaNova PLC (the “Company”) hereby notifies the market that as of 28 February 2017, the Company’s capital consists of 48,178,729 ordinary shares of £1.00 each. The Company does not hold any shares in treasury.

Therefore, the total number of voting rights in the Company is 48,178,729. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interests in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs approximately 4,600 employees.

vLivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.livanova.com, or contact:

Catherine Moroz
Company Secretariat
Phone: +44 (0) 203 325 0662
e-mail: company.secretariat@livanova.com

Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Email: corporate.communications@livanova.com